Response to Temozolomide in Second-Line Treatment of Recurrent Nonsmall Cell Lung Carcinoma: Case Report

2005 ◽  
Vol 23 (2) ◽  
pp. 134-137 ◽  
Author(s):  
Robert A. Somer ◽  
Corey J. Langer
Keyword(s):  
Case Report ◽  
Lung Carcinoma ◽  
Line Treatment ◽  
Second Line ◽  
Cell Lung Carcinoma ◽  
Nonsmall Cell Lung Carcinoma

scholarly journals Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients

Cancer ◽  
2000 ◽  
Vol 88 (6) ◽  
pp. 1353-1358 ◽  
Author(s):  
John D. Hainsworth ◽  
Howard A. Burris ◽  
Sharlene Litchy ◽  
Joan B. Erland ◽  
Jeremy K. Hon ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Line Treatment ◽  
Second Line ◽  
Cell Lung Carcinoma ◽  
Nonsmall Cell Lung Carcinoma

Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma

Cancer ◽  
2001 ◽  
Vol 92 (9) ◽  
pp. 2391-2398 ◽  
Author(s):  
John D. Hainsworth ◽  
Howard A. Burris ◽  
Frederic T. Billings ◽  
James E. Bradof ◽  
Margaret Baker ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Line Treatment ◽  
Second Line ◽  
Cell Lung Carcinoma ◽  
Weekly Docetaxel ◽  
Nonsmall Cell Lung Carcinoma

scholarly journals A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma

2021 ◽  
pp. LMT47
Author(s):  
Jerónimo Rafael Rodríguez-Cid ◽  
Sonia Carrasco-Cara Chards ◽  
Iván Romarico González-Espinoza ◽  
Vanessa García-Montes ◽  
Julio César Garibay-Díaz ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Objective Response ◽  
Small Cell ◽  
Immune Checkpoints ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung ◽  
Total Study Population ◽  
Cell Lung Carcinoma

Background: Immunotherapy has demonstrated an improved overall survival (OS) and progression-free survival (PFS) as second-line treatment and subsequent lines compared with chemotherapy.  Materials and methods: This was a retrospective review among eight medical centers comprising 100 patients with a confirmed diagnosis of non-small-cell lung carcinoma, in their second-line treatment or beyond with immune checkpoints inhibitors treatment. The current study aimed to analyze effectiveness of immunotherapy in second-line treatment or further in the Mexican population, using PFS rate, OS rate and the best objective response to treatment by RECIST 1.1 as a surrogate of effectiveness. Results: In total, 100 patients met the criteria for enrollment in the current study. From the total study population, 49 patients (49.0%) were male and 51 (51.0%) were female, with an average age of 60 years and stage IV as the most prevalent clinical stage at the beginning of the study. A total of 61 patients (61.0%) had partial response; 11 (11.0%) stable disease; 2 (2.0%), complete response, 4 (4.0%), progression; and 22 (22.0%) were nonevaluable. We found a median PFS of 4 months (95% CI: 3.2–4.7 months) and an OS of 9 months (95% CI: 7.2–10.7 months). Conclusion: The response to immunotherapy is similar, with an improvement in OS and PFS, independent of which drug is used. Patients using nivolumab had a better survival, although that was not statistically significant.

scholarly journals Apatinib plus S-1 as second-line or later line treatment for advanced squamous cell lung carcinoma

2018 ◽  
Vol 29 ◽  
pp. ix154-ix155
Author(s):  
Q. Shi ◽  
L. Xia ◽  
J. Zhou ◽  
Z. Wang ◽  
L. Sheng ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Lung Carcinoma ◽  
Line Treatment ◽  
Second Line ◽  
Squamous Cell Lung Carcinoma ◽  
Cell Lung Carcinoma

scholarly journals First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine

Cancer ◽  
1998 ◽  
Vol 83 (10) ◽  
pp. 2083-2090 ◽  
Author(s):  
Charalambos Kourousis ◽  
Nicos Androulakis ◽  
Stelios Kakolyris ◽  
John Souglakos ◽  
George Maltezakis ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Line Treatment ◽  
First Line ◽  
Cell Lung Carcinoma ◽  
Nonsmall Cell Lung Carcinoma ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document